Nivalis Therapeutics

Nivalis Therapeutics, Alpine Immune Sciences to merge

Wednesday, April 19, 2017

Nivalis Therapeutics and Alpine Immune Sciences, a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, have entered into a definitive merger agreement under which Alpine will merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology.

[Read More]

Nivalis Therapeutics restructures

Monday, January 16, 2017

Nivalis Therapeutics, a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), has announced that its board of directors has approved a restructuring plan as part of the company’s initiative to explore strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources.

[Read More]